Devices, systems and methods for mitigating mitral valve regurgitation

The MLC device stabilizes the mitral valve annulus using protective tubes and an anchor to address the challenge of maintaining position and reducing mitral regurgitation through compressive force application.

JP7583036B2Active Publication Date: 2024-11-13TAU MEDICAL INC
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2022520479
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-02
Filing Date
2020-10-02
Publication Date
2024-11-13
Estimated Expiration
2040-10-02

AI Technical Summary

Technical Problem

Existing transcatheter mitral loop circulage devices face challenges in maintaining their position without being pushed back into the coronary sinus, and they struggle to effectively mitigate mitral regurgitation due to cardiomyopathy, mitral annular dilatation, and leaflet traction.

Method used

The MLC device employs a first and second protective tube with a circular rope, a hinge portion, and an anchor to stabilize the device within the coronary sinus and tricuspid valve, ensuring it maintains its position and applies compressive force to the mitral valve annulus.

Benefits of technology

The device effectively reduces mitral regurgitation by stabilizing the mitral valve annulus, preventing advancement into the coronary sinus, and applying tension to alleviate regurgitation, guided by real-time imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007583036000001
    Figure 0007583036000001
  • Figure 0007583036000002
    Figure 0007583036000002
  • Figure 0007583036000003
    Figure 0007583036000003
Patent Text Reader

Abstract

The device for alleviating mitral valve regurgitation includes a first protective tube and a second protective tube. The proximal portions of the two protective tubes are secured adjacent to each other along at least a portion of the length of the two protective tubes to define a stem portion. The distal portions of the two protective tubes are then separated to define a hinge portion. The MLC device has a stopper secured to the distal end of the second protective tube to prevent further advancement of the second protective tube into the myocardium. The first protective tube has at least one anchor disposed between the hinge portion and the distal end of the first protective tube. The anchor is configured to remain within the coronary sinus and maintain the tissue protection device in place.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001]

[0001] The present disclosure relates to devices, systems, and methods for mitigating heart valve regurgitation, and more particularly, to transcatheter devices, systems, and methods for the treatment of mitral valve regurgitation. [Background technology]

[0002]

[0002] Mitral regurgitation is characterized by cardiomyopathy leading to incoaptation, mitral annular dilation, and leaflet traction. The transcatheter mitral loop circumferential ("MLC") device applies a compressive force to the periphery of the mitral annulus by creating a loop through the coronary sinus and spanning the interventricular septum. The mitral loop circumferential device must be able to maintain its position without being pushed back into the coronary sinus. Summary of the Invention

[0003]

[0003] An MLC device for mitigating mitral regurgitation includes a first protective tube and a second protective tube. The MLC device has a circlage rope disposed within the first protective tube and the second protective tube. The first protective tube and the second protective tube each have a proximal end and a distal end. The proximal portions of the two protective tubes are secured side-by-side along at least a portion of the length of the two protective tubes to define a stem portion. The distal portions of the two protective tubes are then separated to define a hinge portion.

[0004]

[0004] The MLC device has a stopper secured to a distal end of the second protective tube to prevent further advancement of the second protective tube into the myocardium. The circlage rope has an arch portion disposed between the distal ends of the two protective tubes. The first protective tube has at least one anchor disposed between the hinge portion and the distal end of the first protective tube. The anchor is configured to remain within the coronary sinus and maintain the tissue protection device in place.

[0005] The first protective tube is configured to be inserted through the coronary sinus to surround at least a portion of the mitral valve, the first protective tube having a preformed shape such that the first tube is configured to maintain the preformed shape as the first tube moves through the coronary sinus.

[0006]

[0006] The second protective tube is configured to pass through the tricuspid valve and rest against the right ventricular side of the ventricular septum. The second protective tube has a preformed shape such that the second tube is configured to maintain the preformed shape as the second tube moves through the tricuspid valve. The second protective tube has sufficient stiffness to resist bending inward when tension is applied.

[0007]

[0007] A method of treating mitral regurgitation in a patient using an MLC device includes the steps of: (a) inserting a sheath introducer into the femoral vein; (b) inserting a guide catheter through the femoral sheath that engages into the coronary sinus; (c) moving the guidewire into the interventricular septum and out into the right ventricular (RV) cavity; (d) placing a guidewire capture through the femoral sheath into the right ventricular cavity and grasping the exiting guidewire; (e) withdrawing the guidewire using the guidewire capture to the femoral sheath such that the guidewire defines a femoral vein pathway that is: inferior vena cava (IVC)-coronary sinus (CS)-right ventricular (RV) cavity-right atrium (RA)-inferior vena cava (IVC)-femoral vein; and (f) The method includes the steps of: (g) connecting the proximal end of the guidewire to the circlage rope using a tension locking device; (h) advancing the MLC device over the circlage rope within the femoral sheath using a delivery system; (i) securing an anchor to hold the MLC device in place when the tension in the MLC device is optimal; (j) transmitting a suitable tension through the tension locking device guided by real-time imaging, such as an echocardiogram, when the MLC device is in place; and (k) severing the circlage rope with a cutting device.

[0008]

[0008] Features and advantages of the claimed subject matter will become apparent from the following description of the embodiments thereof, which description should be considered in conjunction with the accompanying drawings, in which: [Brief description of the drawings]

[0009] [Figure 1] FIG. 2 is a diagram of an embodiment of an MLC device including a stem section, a first tube, and a second tube.

[0010] [Diagram 2] FIG. 13 is a diagram of an embodiment of an MLC device showing the hinge portion and the stopper on the second arm.

[0011] [Diagram 3] FIG. 1 is a diagram of an embodiment of an MLC device showing the lumen of the stopper and the lumen of the first arm.

[0012] [Figure 4] FIG. 1 illustrates an embodiment of a circle large rope including an arch portion and an outer layer.

[0013] [Diagram 5] FIG. 1 illustrates an embodiment of a circle large rope including an arch portion and an outer layer.

[0014] [Figure 6] 1A-1C are diagrams of an embodiment of an MLC device as it advances along a circular rope.

[0015] [Figure 7] 1A-1C are diagrams of an embodiment of an MLC device as it advances along a circular rope.

[0016] [Figure 8] 1A-1C are diagrams of an embodiment of an MLC device as it advances along a circular rope.

[0017] [Figure 9] FIG. 2 is a diagram of an embodiment of an MLC device illustrating how the MLC device is advanced along a circular rope.

[0018] [Figure 10A] FIG. 1 illustrates a procedure in which coronary venography via a balloon wedge catheter identifies the primary septal perforator coronary vein through which a guidewire is advanced.

[0019] [Figure 10B]FIG. 13 is a diagram of a procedure in which a target capture device is placed in the right ventricular outflow tract to capture a guidewire coming from a coronary vein.

[0020] [Figure 10C] 13A-13C are diagrams of a procedure in which a guidewire is replaced with a tensioning device including an integrated coronary vein protection element.

[0021] [Figure 10D] 13A-13D are diagrams of a procedure in which a protective element prevents compression of a captured circumflex coronary vein while under tension.

[0022] [Figure 10E] FIG. 13 is a procedural diagram in which the mitral loop circumambulation system is shown encircling the mitral annulus plane in this caudal left anterior oblique projection.

[0023] [Figure 10F] FIG. 13 is a diagram of a procedure in which a tension locking device is implanted in the left subclavian pocket.

[0024] [Figure 11] FIG. 13 shows a tension locking device implanted in the left subclavian pocket.

[0025] [Figure 12] FIG. 2 illustrates an embodiment of an MLC device when under relaxed tension.

[0026] [Figure 13] FIG. 2 illustrates an embodiment of an MLC device under tension.

[0027] [Figure 14] FIG. 13 illustrates the placement of stoppers on the walls of the IVS.

[0028] [Figure 15] FIG. 2 illustrates the first arm encircling the mitral valve.

[0029] [Figure 16] FIG. 13 illustrates an anchor being installed on a first arm.

[0030] [Figure 17] FIG. 13 illustrates an anchor being installed on a first arm.

[0031] [Figure 18] FIG. 13 illustrates an anchor being installed on a first arm.

[0032] [Figure 19] 1 depicts an embodiment of an anchor.

[0033] [Figure 20] FIG. 1 illustrates an anchor being placed within the coronary sinus.

[0034] [Figure 21] FIG. 1 depicts preferred anchoring sites.

[0035] [Figure 22] FIG. 1 depicts other possible anchoring sites that are preferred. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] Disclosure

[0036] In the drawings, like numerals refer to like elements throughout. Certain terminology used herein is merely for convenience and should not be construed as limiting the invention. The terms "distal" and "proximal" refer to directions "away from" and "closer to" the body of the physician inserting the introducer sheath into the patient, respectively. These terms include those specifically mentioned above, derivatives thereof, and words of similar importance.

[0037]

[0037] The Mitral Loop Circulation ("MLC") device 10 may include a first tube 20 and a second tube 30, as shown in Figure 1. The first tube 20 may be configured to engage with the coronary sinus (CS). The second tube 30 may be configured to engage with the tricuspid valve (TV).

[0038] 2, the first tube 20 has a proximal end 22 and a distal end 23 and an expanding lumen 24. The second tube 30 similarly has a proximal end 32 and a distal end 33 and a lumen 34 extending therebetween. The proximal portions of the first tube 20 and the second tube 30 can be secured longitudinally adjacent to each other along at least a portion of the length of the two tubes 20, 30 to define the trunk section 14, and the distal portions of the first tube 20 and the second tube 30 can then be separated to define the hinge section 16. The first tube 20 and the second tube 30 can be formed of a soft material, such as, for example, a synthetic material, rubber, soft plastic, or a metallic material, such as, for example, a coil spring. trunk part

[0039]

[0039] As shown in Figures 1-2, the MLC device 10 can include a stem section 14. The proximal portions of the first tube 20 and the second tube 30 can be secured together longitudinally side-by-side and then separated from one another distally. The secured portion between the first tube 20 and the second tube 30 is defined as the stem section 14. The portion where the two tubes 20, 30 begin to separate is defined as the hinge section 16. The length of the stem section 14 can vary as needed.

[0040] The role of the trunk section 14 is to stabilize the first tube 20 and the second tube 30 so that their positions may be maintained. When the hinge portion 16 rests against the entrance to the coronary sinus, it prevents the MCL device 10 from advancing into either the coronary sinus or the tricuspid valve. Hinge part

[0041] 1-2, the MLC device 10 can include a hinge portion 16. The hinge portion 16 is defined as where the first tube 20 and the second tube 30 begin to separate from one another. As shown in FIGS. 12-13, the hinge portion 16 can be located at or near the entrance to the coronary sinus.

[0042] The role of the hinge portion 16 is to stabilize the first tube 20 and the second tube 30 so that their positions may be maintained. When the hinge portion 16 comes to rest against the entrance to the coronary sinus, it prevents the MCL device 10 from advancing into either the coronary sinus or the tricuspid valve. First arm for the mitral valve

[0043]

[0043] The first tube 20 may include a lumen 24 extending between a proximal end 22 and a distal end 23. As shown in Figure 2, a first arm portion 21 of the first tube 20 is defined as the portion from the hinge portion 16 to the distal end 23. As shown in Figures 1-2, the first arm portion 21 may be preformed from a soft material, such as, for example, a synthetic material, rubber, soft plastic, or a metallic material, such as, for example, a coil spring, so that the first arm portion 21 maintains a preformed shape as it moves through the coronary sinus. Figures 12-13 show the first arm portion 21 moving through the coronary sinus.

[0044]

[0044] The first arm portion 21 is configured to be inserted through the coronary sinus and surround at least a portion of the mitral valve. As shown in Figure 13, the first arm portion 21 is configured to clamp the mitral valve annulus when tensioned to reduce regurgitation.

[0045] When the circlage rope 50 is inserted into the MLC device 10, the first arm portion 21 prevents direct contact of the circlage rope 50 and protects the coronary sinus and surrounding tissue from damage. The length of the first arm portion 21 may vary from patient to patient as needed. The length may be determined based on estimates from prior imaging of the individual patient. Second arm for tricuspid valve

[0046] The second tube 30 may include a lumen 34 extending between a proximal end 32 and a distal end 33. As shown in FIG. 2, the second tube 30 includes a second arm portion 31 defined as the portion between the hinge portion 16 and the distal end 33 of the second tube 30.

[0047]

[0047] The second arm portion 31 is configured to pass through the tricuspid valve. As shown in Figures 1-2, the second arm portion 31 may be preformed with soft materials, such as synthetic materials, rubber, soft plastics, or metal materials, such as coil springs, so that it maintains a preformed shape as it passes through the tricuspid valve. The second arm portion 31 may be sufficiently rigid to resist bending when tension is applied to the circlage rope 54. Figures 12-14 show the second arm portion 31 passing through the tricuspid valve. The length of the second arm portion 31 may vary from patient to patient as needed. The length may be determined based on estimates from prior imaging of the individual patient. stopper

[0048]

[0048] The second tube 30 also includes a stopper 40. The stopper 40 may be secured to a distal portion of the second tube 30. The stopper 40 may preferably be securely secured to the distal end 33 of the second tube 30 as shown in Figs. 1-2. The stopper 40 is configured to rest against the right ventricular side of the ventricular septum as shown in Figs. 12-14. The stopper 40 is configured to continue to cause the second arm portion 31 to maintain its preformed shape and position by resting against the ventricular septum. The stopper 40 also keeps the second arm portion 31 floating rather than in direct contact with the tricuspid valve when tension is applied to the circlage rope 50. Additionally, the stopper 40 prevents the distal end 33 of the second tube 30 from advancing into the ventricular septum.

[0049]

[0049] As shown in Figures 7-8, the stopper 40 can include a central lumen 41 through which the circle large rope 50 can travel. The size, shape, and volume of the stopper 41 can vary as needed for different patients, but should be larger in diameter than the second arm portion 31. Those skilled in the art will recognize that the stopper 40 can have shapes other than a disk as shown in Figure 7. Tension Circle Large Rope

[0050]

[0050] Figure 4 shows the circlage rope 50. The circlage rope 50 has an arch portion 51. As shown in Figures 4-5, the arch portion 51 is covered by an outer layer 52. The outer layer 52 is integrally coated on the arch portion 51. The outer layer is preferably longer and can be tapered toward the stopper 40 as shown in Figure 8. The arch portion 51 and its outer layer 52 are configured to protect the coronary vein and the surrounding heart tissue when tension is applied to the circlage rope 50.

[0051]

[0051] The circle large rope 50 may be made of a synthetic material such as nylon, metal (ie, stainless steel), or metal coated with nylon, etc. The coated portion 52 may be made of a biocompatible synthetic resin. anchor

[0052]

[0052] A preferred embodiment of the MLC device 10 further comprises an anchor 70. As shown in Figures 16-17, the anchor 70 is preferably located on the first arm portion 21 near the hinge portion 16. The anchor 70 may also be located elsewhere along the first arm portion 21.

[0053] 21-22 show the locations of multiple anchors 40 along either the first arm portion 21 and / or the second arm portion 31. Preferred anchor 40 locations are marked with circles along the first arm portion 21 near the hinge portion 16. Other possible anchor locations on the first arm portion 21 and the second arm portion 31 are marked with squares. The anchors 70 are configured to maintain the MLC device 10 in place and prevent further advancement of the device 10 into the coronary sinus when tension may be applied by the circlage rope 50.

[0054]

[0054] As shown in Figures 17-19, the anchor 70 may include at least one anchor head 71 and at least one anchor arm 72. The anchor head 71 is configured to remain at a preferred anchoring site as shown in Figure 21. The anchor arm 72 is configured to be secured firmly onto the first arm portion 21 and / or the second arm portion 31. Multiple anchors 70 may be secured firmly onto the first arm portion and / or the second arm portion 31. Mitral Loop Circulation (MLC) Procedure

[0055] Under conscious sedation (n=3) or general anesthesia (n=2), 19F x 15 cm introducer sheaths (Oscor, Palm Harbor, FL) may be placed in both the left subclavian and femoral veins (via a pacemaker-like pocket). The operator may then stand at the right groin. Transesophageal echocardiography (TEE) under anesthesia or transthoracic echocardiography under sedation may be used to interactively adjust tension to mitigate MR. Heparin may be administered to achieve an activated clotting time of >300 seconds.

[0056]

[0056] A balloon-tipped coronary sinus guide catheter (Cello, Medtronic) is placed into the great cardiac vein through the left subclavian vein, and pressurized contrast venography is performed. A two-lumen 0.014-inch microcatheter (Crusade, Kaneka Medics, Osaka, Japan) is placed along with a soft 0.014-inch guidewire (Whisper, Abbott, Chicago, Illinois) through the coronary sinus guide into the basic septal perforator coronary vein, which may then be used to guide a stiff-tipped 0.014-inch peripheral guidewire (Astato XS20, Asahi Intecc Co., Ltd., Japan) across the interventricular septum and into the RVOT. As shown in Figure 10A, coronary venography via the balloon wedge catheter can identify the basic septal perforator coronary vein (arrowhead mark) through which the guidewire can be advanced.

[0057] A transfemoral balloon wedge end-hole catheter can be advanced through the large tricuspid orifice into the pulmonary artery and then replaced with a wallstent / snare combination that functions as a target and capture system in the right ventricular outflow tract (RVOT). The traveling guidewire can be captured once inside the RVOT and externalized via the femoral vein. As shown in FIG. 10B, a target capture device can be placed in the RVOT to capture the guidewire coming from the coronary vein.

[0058]

[0058] The Circlage Rope 50 is attached to the guidewire using heat shrink tubing (polyether block amide, Cobalt Polymers, Cloverdale, Calif.) and then pulled into position through the coronary sinus and interventricular septum. The distal tip of the guidewire can be transferred from the femoral sheath to the subclavian sheath using a loop snare. As shown in FIG. 10C, the guidewire can be replaced with the Circlage Rope 50, which includes an integral arch portion 51 (arrowhead mark).

[0059]

[0059] The MLC device 10 can then be advanced along the two free ends 55, 56 of the circlage rope 50. Figure 9 shows the straightened first and second arm portions 21, 31 of the first and second tubes 20, 30 housed within the sheath. Once the circlage rope 50 is in place, the straightened first and second arm portions 21, 31 of the MLC device 10 are routed over the two ends 55, 56 of the circlage rope 50, originating from the distal end 23 of the first tube 20 and the distal end 33 of the second tube 30. As shown in Figure 11, when the MLC device 10 is in place within the heart, the first and second arm portions 21, 31 are restored to their preformed shapes.

[0060]

[0060] Diagnostic coronary venography may allow precise positioning of the arched portion 51 incorporated into the circumaurge rope 50. As shown in Figure 10D, while under tension, the arched portion 51 may prevent compression of the captured circumflex coronary vein.

[0061]

[0061] Tension may be interactively applied during transthoracic echocardiography or TEE to achieve the intended reduction in mitral annulus size and mitral regurgitation. As shown in FIG. 10E, in this caudal left anterior oblique projection, the MLC device 10 is shown encircling the mitral annulus plane. Finally, tension may be locked in the left subclavian pocket and the skin incision may be closed. As shown in FIG. 10F, a tension locking device 58 may be implanted in the left subclavian pocket. MLC Transfemoral Procedure

[0062] In addition to the above procedures, a transfemoral procedure of MLC may also be performed. The transfemoral procedure may include the following steps: (1) inserting a sheath introducer into the femoral vein; (2) inserting a guiding catheter through the femoral sheath that engages into the coronary sinus; (3) moving a 0.014 inch guidewire into the interventricular septum and out into the right ventricular (RV) cavity; (4) placing a wire capture through the femoral sheath into the RV cavity and grasping the exiting guidewire; (5) drawing the guidewire out using the capture to the femoral sheath so that the guidewire follows the femoral vein path: inferior vena cava (IVC)-coronary sinus (CS)-RV cavity-right atrium (RA)-IVC-femoral vein; (6) securing the proximal end of the guidewire with a tension lock system. (7) replacing the guidewire in place with the circlage rope 50 by pulling on the distal end of the guidewire; (8) advancing the MLC device over the circlage rope 50 within the femoral sheath using a delivery system; (9) when the tension in the MLC 10 is optimal, securing an anchor 70 to hold the MLC in place; (10) when the MLC device is in place, a suitable tension is delivered through the tension lock device 58 guided by real-time imaging such as an echocardiogram; and (11) severing the circlage rope 50 with a special cutting device.

[0063]

[0063] The advantages and features of the present invention, as well as the methods for achieving them, will become apparent from the following detailed description of the embodiments in conjunction with the accompanying drawings. However, the present invention is not limited to the embodiments disclosed below, and may be implemented in various different forms. These embodiments are provided to complete the disclosure of the present invention and to fully convey the scope of the present invention to those skilled in the art, and the present invention is defined solely by the claims.

Claims

1. 1. A device for mitigating mitral regurgitation comprising a first protective tube and a second protective tube, the device having a circlage rope disposed within the first protective tube and the second protective tube, the first protective tube and the second protective tube each having a proximal end and a distal end, the proximal portions of the two protective tubes being secured side-by-side along at least a portion of the length of the two protective tubes to define a stem portion, and the distal portions of the two protective tubes being subsequently separated to define a hinge portion, the device having a stopper secured to the distal end of the second protective tube and configured to prevent further advancement of the second protective tube into the myocardium, the circlage rope having an arch portion disposed between the distal ends of the two protective tubes, the first protective tube having at least one anchor disposed between the hinge portion and the distal end of the first protective tube, the anchor configured to remain within the coronary sinus and maintain the device in place, A device, wherein the anchor has an anchor head attached to a peripheral surface of the first protective tube and an anchor arm extending from the anchor head along a direction intersecting the first protective tube.

2. The device of claim 1 , wherein the first protective tube is configured to be inserted through the coronary sinus and surround at least a portion of the mitral valve.

3. 2. The device of claim 1, wherein the first protective tube has a preformed shape such that the first protective tube is configured to maintain the preformed shape as the first protective tube moves through the coronary sinus.

4. 10. The device of claim 1, wherein the second protective tube is configured to pass through the tricuspid valve and come to rest against the right ventricular side of the ventricular septum.

5. 2. The device of claim 1, wherein the second protective tube has a preformed shape such that the second protective tube is configured to maintain the preformed shape as the second protective tube moves through a tricuspid valve.

6. The device of claim 1 , wherein the second protective tube has sufficient stiffness to resist bending inwardly when subjected to tension.

Citation Information

Patent Citations

  • Tissue protection device for tricuspid regurgitation surgery

    EP3158940A1

  • Coronary sinus and tricuspid valve organ protection devices, nodular transmission devices, and mitral valve circulatory devices including these.

    JP2013537084A

  • Tissue protective device for the cerclage annuloplasty procedure in use of the coil spring, and tissue protective device making method

    KR1020150136910A

  • Catheter for preventing the damage of tricuspid valve in the mitral cerclage coronary sinus annuloplasty

    KR1020160029548A

  • Mitral cerclage annuloplasty method

    US20190269503A1